Format

Send to

Choose Destination
J Psychopharmacol. 2018 Jun;32(6):641-653. doi: 10.1177/0269881118756245. Epub 2018 Feb 27.

Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders.

Author information

1
1 Department of Child and Adolescent Psychiatry, King's College London, UK.
2
3 HealthTracker Ltd., Gillingham, UK.
3
2 Centre for Interventional Paediatric Psychopharmacology and Rare Diseases, South London and Maudsley NHS Foundation Trust, UK.

Abstract

OBJECTIVES:

To date, there is no single medication prescribed to alleviate all the core symptoms of Autism Spectrum Disorder (ASD; National Institute of Health and Care Excellence, 2016). Both serotonin reuptake inhibitors and drugs for psychosis possess therapeutic drawbacks when managing anxiety and aggression in ASD. This review sought to appraise the use of propranolol as a pharmacological alternative when managing emotional, behavioural and autonomic dysregulation (EBAD) and other symptoms.

MATERIALS AND METHODS:

Sixteen reports examined the administration of propranolol in the context of ASD.

RESULTS:

Sixteen reports broadly covered cognitive domains, neural correlates, and behavioural domains. From the eight single-dose clinical trials, propranolol led to significant improvements in cognitive performance - verbal problem solving, social skills, mouth fixation, and conversation reciprocity; and changes in neural correlates - improvement in semantic networks and functional connectivity. The remaining eight case series and single case reports showed improvements in EBAD, anxiety, aggressive, self-injurious and hypersexual behaviours. Additionally, propranolol significantly improved similar behavioural domains (aggression and self-injury) for those with acquired brain injury.

CONCLUSION:

This review indicates that propranolol holds promise for EBAD and cognitive performance in ASD. Given the lack of good quality clinical trials, randomised controlled trials are warranted to explore the efficacy of propranolol in managing EBAD in ASD.

KEYWORDS:

ASD; Autism Spectrum Disorder; EBAD; aggression; anxiety; beta-blockers; propranolol

PMID:
29484909
DOI:
10.1177/0269881118756245

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center